BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Canoo

Next week's earnings reports get off to a slow start, with just one report of interest coming Monday after markets close and one more before markets open Tuesday morning.

Earnings Previews: Canoo, BioNTech

BioNTech SE said Friday that the European Medicines Agency (EMA) has approved its Marburg facility in Germany for the manufacture of the COVID-19 vaccine drug substance, which would boost annual vaccine production capacity by one billion does a year when full operational. BioNTech, which along with U.S.-based partner Pfizer Inc. makes the COVID-19 vaccine, said it can now deliver the drug product batches of the vaccine to partner sites, for sterile fill and finish, and expects the first batches of the vaccines made at the Marburg site to be delivered in the second half of April.

BioNTech's Marburg facility gets EMA approval, boosting COVID-19 vaccine production capacity by a billion doses a year

MAINZ, GERMANY, March 26, 2021 (GLOBE NEWSWIRE) — BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part of the process, EMA has approved the production of the drug substance, the mRNA, at the Marburg site over the course of this week. The approvals make BioNTech's Marburg manufacturing site one of the largest mRNA vaccine manufacturing sites in Europe as well as worldwide with an annual production capacity of up to one billion doses of our COVID-19 vaccine, once fully operational. Due to optimized operational efficiencies which were initiated last year, BioNTech has been able to increase the expected annual manufacturing capacity by 250 million doses.

BioNTech provides Update on Vaccine Production Status at Marburg Manufacturing Site

New York and Mainz, Germany, March 26 , 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the European Medicines Agency (EMA) approved storage of COMIRNATY® at -25°C to -15°C for a total of two weeks based on data showing the stability at these temperatures in standard pharmaceutical freezers. The new data is a testament to the companies' ongoing commitment to developing this vaccine further and collecting data in order to support broader and more flexible vaccine distribution and inoculation. With this approval, the COMIRNATY vials can be stored in all 27 European Union (EU) member states at these updated temperatures for a total of two weeks alternatively to the storage at ultra-low temperatures. It marks an important milestone in the vaccine roll-out, as it could allow storage in pharmacies to support vaccinations at local practices/doctors' offices. By enabling more individuals to store and administer the vaccine, the approval will help broaden access, while limiting strain on larger vaccination centers.

EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union

The company, which developed its Covid-19 vaccine with Pfizer, partners with Shanghai Fosun Pharmaceutical on the vaccine in greater China.

Hong Kong Halts Use of BioNTech Vaccine Over Packaging Issues

AstraZeneca

Johnson & Johnson

Moderna

Novavax

Pfizer

Viatris

This question has multiple right answers.

Which COVID Vaccine Stock Is the Best Pick?

Vaccine maker BioNTech and its Chinese partner Fosun Pharma say they have found no reason to believe the defect may have caused a safety issue.

Hong Kong Suspends Use Of Pfizer-BioNTech Vaccine Due To Defective Bottle Lids

Shares of Shanghai Fosun Pharmaceutical Group in Hong Kong plunged more than 5% in Wednesday morning trade.

Fosun Pharma shares tumble more than 5% as Hong Kong suspends BioNTech Covid vaccinations

The pharmaceutical heavyweight thinks it won't need any more help to whip up new mRNA-based vaccines.

Pfizer to Develop mRNA Vaccines Without BioNTech

Mainz, Germany, March 23, 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter 2020 on Tuesday, March 30th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CET) to report its financial results and provide a corporate update on the fourth quarter and full year 2020.

BioNTech to Report Full Year Financial Results for 2020 and Provide Corporate Update on the Fourth Quarter on March 30, 2021

Some stocks could be big winners and losers depending on what the answer to this question is.

The Multibillion-Dollar Question: How Long Do COVID Vaccines Last?

Some vaccine makers are better positioned than others.

Which COVID Stocks Are the Best Picks if Coronavirus Variants Spread?

Pfizer is looking to turn its lucrative coronavirus vaccine into an even bigger cash cow. The drugmaker sees a “significant opportunity” to charge more for the groundbreaking shot once it gets to the other side of the COVID-19 pandemic, one top executive says.

Pfizer sees ‘opportunity' to hike price for COVID-19 vaccine, CFO says

Pfizer execs have informed the company's investors of a "significant opportunity" to hike the prices of the Pfizer-BioNTech vaccine. Speaking at the virtual Barclays Global Healthcare Conference last week, two high-ranking Pfizer employees – CFO Frank D'Amelio and Chuck Triano, senior VP of investor relations – said there would be a chance for Pfizer to raise prices for the vaccine when COVID moves from a pandemic state to an endemic situation and the virus circulates continually in pockets around the globe.

Pfizer execs say there's a 'significant opportunity' to hike prices of its COVID vaccine

Don't jump to any conclusions based on the different vaccines' advisory committee votes.

Is Johnson & Johnson's COVID Vaccine Actually Better Than Pfizer's and Moderna's Vaccines?

Pfizer Inc.'s stock may have lost ground last year, and so far this year, while its peer group gained ground, but 2020 could still be considered a good year for the health care company, as it developed, along with its partner BioNTech SE , one of the three COVID-19 vaccines in use in the U.S. It was certainly a good year for Chief Executive Albert Bourla, whose total compensation increased 17.3% to $21,033,570, from $17,928,963 in 2019, according to a proxy filing on Friday. His 2020 compensation included a salary of $1,650,000, was well as option award, non-equity incentive plan compensation and stock awards.

Pfizer CEO compensation jumped 17% in 2020, as COVID-19 vaccine was developed but stock fell

There was some excellent news about the company's most famous product.

Why BioNTech Trounced the Market on Thursday

Adaptive Biotechnologies

Amgen

Illumina

Microsoft

The confluence of healthcare and technology will send many biotech stocks soaring over the next decade.

Why You Should Own Biotech Stocks Now

Results from Israel suggest the Pfizer-BioNTech vaccine works even better than its phase 3 trial results indicated.

Pfizer's Vaccine 97% Effective at Preventing COVID-19 in Real-World Study

New evidence unveiled Thursday suggests Pfizer and BioNTech's coronavirus vaccine is at least 97% effective two weeks after the second dose. In early action, BNTX stock jumped.

BioNTech Stock: Evidence Suggests Covid Vaccine Is Almost 100% Effective

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) said that real-world data from Israel suggests that their COVID-19 vaccine is 94% effective in preventing asymptomatic infections, thus having the potential to reduce transmission significantly. The companies also said the latest analysis of the Israeli data showed the vaccine was 97% effective in preventing symptomatic disease, severe disease, and death, in line with the 95% efficacy reported in December.

Pfizer/BioNTech's COVID-19 Vaccine Can Prevent Asymptomatic Infection, Study Shows

Pfizer said its Covid-19 vaccine blocked 94% of asymptomatic infections in an Israeli study – a result CEO Albert Bourla called "extremely important."

Pfizer Covid vaccine blocks 94% of asymptomatic infections and 97% of symptomatic cases in Israeli study

Pfizer and its German partner BioNTech have indicated that they should have the capacity to produce as many as three billion doses of their Covid-19 vaccine in 2022, subject to demand. For perspective, Pfizer intends to produce about 2 billion doses of its shot this year and is projecting about.

Pfizer Covid-19 Vaccine Updates: Will Demand Cool In 2022, Despite Growing Capacity?

Pfizer Inc. and BioNTech SE , along with the Israel Ministry of Health, said a real-world study showed "dramatically lower" rates of COVID-19 cases in people vaccinated with the companies' BNT162b2 vaccine. The data also showed that protection from COVID-19 is even stronger two weeks after the second dose was taken.

Pfizer, BioNTech real-world study shows COVID-19 vaccine 'dramatically' lowers cases, hospitalizations and deaths

JERUSALEM, NEW YORK and MAINZ, GERMANY, March 11, 2021 -  The Israel Ministry of Health (MoH), Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel's nationwide immunization program. These new data build upon and confirm previously released data from the MoH demonstrating the vaccine's effectiveness in preventing symptomatic SARS-CoV-2 infections, COVID-19 cases, hospitalizations, severe and critical hospitalizations, and deaths. The latest analysis from the MoH proves that two weeks after the second vaccine dose protection is even stronger – vaccine effectiveness was at least 97% in preventing symptomatic disease, severe/critical disease and death. This comprehensive real-world evidence can be of importance to countries around the world as they advance their own vaccination campaigns one year after the World Health Organization (WHO) declared COVID-19 a pandemic.

Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared

News for BioNTech SE Stock (BNTX)